Clinical and molecular models of Glioblastoma multiforme survival

  • Authors:
  • Stephen R. Piccolo;Lewis J. Frey

  • Affiliations:
  • Department of Pharmacology and Toxicology, University of Utah, 201 Presidents Circle, Salt Lake City, 84112 UT, USA;Department of Biomedical Informatics and Huntsman Cancer Institute, University of Utah, 26 South 2000 East Room 5775 HSEB, Salt Lake City, UT 84112, USA

  • Venue:
  • International Journal of Data Mining and Bioinformatics
  • Year:
  • 2013

Quantified Score

Hi-index 0.00

Visualization

Abstract

Glioblastoma multiforme GBM, a highly aggressive form of brain cancer, results in a median survival of 12-15 months. For decades, researchers have explored the effects of clinical and molecular factors on this disease and have identified several candidate prognostic markers. In this study, we evaluated the use of multivariate classification models for differentiating between subsets of patients who survive a relatively long or short time. Data for this study came from The Cancer Genome Atlas TCGA, a public repository containing clinical, treatment, histological and biomolecular variables for hundreds of patients. We applied variable-selection and classification algorithms in a cross-validated design and observed that predictive performance of the resulting models varied substantially across the algorithms and categories of data. The best-performing models were based on age, treatments and global DNA methylation. In this paper, we summarise our findings, discuss lessons learned in analysing TCGA data and offer recommendations for performing such analyses.